Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This observational study will assess the treatment duration, progression-free survival,
reason for stopping treatment and patient and tumor characteristics of bevacizumab [Avastin]
treatment in patients with metastatic colorectal cancer. Data will be collected for
approximately 34 months. The target sample size is >300 patients.